MYC rearrangements have been identified in 14% of newly diagnosed Diffuse large B cell lymphoma (DLBCL) and represent a subset of DLBCL with aggressive behavior and poor overall outcomes when treated with first line therapy [18, 19]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.